Search
Results: 3
Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
Neha Mishra, Konrad Aden, Johanna I Blase, Nathan Baran, Dora Bordoni, Florian Tran, Claudio Conrad, Diana Avalos, Charlot Jaeckel, Michael Scherer, Signe B Sørensen, Silja H Overgaard, Berenice Schulte, Susanna Nikolaus, Guillaume Rey, Gilles Gasparoni, Paul A Lyons, Joachim L Schultze, Jörn Walter, Vibeke Andersen, SYSCID Consortium, Emmanouil T Dermitzakis, Stefan Schreiber, Philip Rosenstiel
Sep 25, 2022
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.
Inga H Rye, Anne Trinh, Anna B Saetersdal, Daniel Nebdal, Ole Christian Lingjaerde, Vanessa Almendro, Kornelia Polyak, Anne-Lise Børresen-Dale, Åslaug Helland, Florian Markowetz, Hege G Russnes
Mar 04, 2019
Targeted therapy for patients with HER2-positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and...
Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
Neha Mishra, Konrad Aden, Johanna I Blase, Nathan Baran, Dora Bordoni, Florian Tran, Claudio Conrad, Diana Avalos, Charlot Jaeckel, Michael Scherer, Signe B Sørensen, Silja H Overgaard, Berenice Schulte, Susanna Nikolaus, Guillaume Rey, Gilles Gasparoni, Paul A Lyons, Joachim L Schultze, Jörn Walter, Vibeke Andersen, SYSCID Consortium, Emmanouil T Dermitzakis, Stefan Schreiber, Philip Rosenstiel
Oct 25, 2022
BACKGROUND AND AIMS: Treatment with tumor necrosis factor α (TNFα) antagonists in IBD patients suffers from primary non-response rates of up to 40%. Biomarkers for early prediction of therapy success are missing. We investigated...